<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18019">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872311</url>
  </required_header>
  <id_info>
    <org_study_id>MCL10416</org_study_id>
    <nct_id>NCT02872311</nct_id>
  </id_info>
  <brief_title>Open-Label Influenza Vaccine Evaluation</brief_title>
  <acronym>OLIVE</acronym>
  <official_title>Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshfield Clinic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Marshfield Clinic Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized trial in up to 180 adults aged 65-74 years to evaluate the
      immune response to standard dose, high dose, and adjuvanted influenza vaccine across 2
      seasons. Participants will be randomized to receive 1 of 3 licensed and recommended vaccines
      and will have pre and post-vaccination serum blood draws for a total of 6 draws over 18
      months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean Hemagglutination inhibition (HI) Antibody Titers</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric mean Hemagglutination inhibition (HI) antibody titers at each time point will be compared by vaccine group</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered Fluzone High Dose (HD) influenza vaccination in the first year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered FluAd influenza vaccination in the first year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered a Fluzone standard dose flu vaccination in the first year of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Dose Influenza vaccine</intervention_name>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <other_name>Fluzone HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Influenza vaccine</intervention_name>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <other_name>FluAd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Influenza vaccine</intervention_name>
    <arm_group_label>Standard Dose Influenza Vaccine</arm_group_label>
    <other_name>Fluzone Standard Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65-74 years at the time of study enrollment and are ambulatory and live in
             selected Wisconsin community or surrounding communities.

          -  Willing and able to give informed consent prior to study enrollment

          -  Able to comply with study requirements.

        Exclusion Criteria:

          -  Prior receipt of 2016-17 influenza vaccine

          -  Current participation in another clinical trial

          -  Presence of a contraindication to influenza vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer King, MPH</last_name>
    <phone>715-389-5088</phone>
    <email>king.jennifer@mcrf.mfldclin.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 19, 2016</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshfield Clinic Research Foundation</investigator_affiliation>
    <investigator_full_name>Huong McLean, PhD</investigator_full_name>
    <investigator_title>Associate Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Influenza</keyword>
  <keyword>High Dose</keyword>
  <keyword>Adjuvanted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
